PGNX Progenics Pharmaceuticals Inc. featured news, full reports, and detailed charts
Progenics Pharmaceuticals Inc. (PGNX) Wrap Up:
Progenics Pharmaceuticals, Inc. is a biopharmaceutical company focusing on the development and commercialization of innovative therapeutic products to treat the unmet medical needs of patients with debilitating conditions and life-threatening diseases. Our principal programs are directed toward gastroenterology, virology and oncology. We commenced principal operations in late 1988, and since that time we have been engaged primarily in research and development efforts, development of our manufacturing capabilities, establishment of corporate collaborations and raising capital. We do not currently have any commercial products. Gastroenterology In the area of gastroenterology, our work is focused on methylnaltrexone, which is our most advanced product candidate. ... More..."http://secfilings.nasdaq.com/edgar_conv_html%2f2008%2f03%2f17%2f0000835887-08-000013.html#FIS_BUSINESS"www.progenics.com
244 Employees
Founded in 1986
Progenics Pharmaceuticals Inc. (PGNX:NASDAQ)
LAST $4.07 USD
CHANGE TODAY +0.08 2.01%
VOLUME 307.7K
As of 4:00 PM 11/20/09 All times are local (Market data by Reuters is delayed by at least 15 minutes).
Snapshot of Progenics Pharmaceuticals Inc. (PGNX)
|
OPEN
$3.99
|
PREVIOUS CLOSE
$3.99
|
|
|
DAY HIGH
$4.09
|
DAY LOW
$3.93
|
|
|
52 WEEK HIGH
01/2/09 - $10.81
|
52 WEEK LOW
11/12/09 - $3.53
|
|
|
MARKET CAP
128.9M
|
AVERAGE VOLUME 3 mo
220.9K
|
|
|
DILUTED EPS TTM
$-1.44
|
SHARES OUTSTANDING
31.7M
|
|
|
PGNX Does Not Pay Dividends
|
P/E TTM
NM
|
|
| K = Thousands M = Millions B = Billions | ||
PGNX Top Compensated Officers
Dr. Paul J. Maddon M.D., Ph.D.
Founder, Chief Executive Officer, Chief Scien...
Age: 49
Total Annual Compensation: $948.0K
Mr. Mark R. Baker J.D.
President and Director
Age: 54
Total Annual Compensation: $545.0K
Mr. Robert A. McKinney CPA
Chief Financial Officer, Principal Accounting...
Age: 52
Total Annual Compensation: $378.0K
Dr. Thomas A. Boyd Ph.D.
Senior Vice President of Product Development
Age: 57
Total Annual Compensation: $445.0K
Dr. Robert J. Israel M.D
Senior Vice President of Medical Affairs
Age: 52
Total Annual Compensation: $435.0K
Executives, Board Directors
Compensation as of Fiscal Year 2008.
Key developments for Progenics Pharmaceuticals Inc. (PGNX)
Progenics Pharmaceuticals Inc. Announces Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2009
11/9/2009
Progenics Pharmaceuticals Inc. announced unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2009. Net loss for the third quarter of 2009 was $13.0 million or $0.41, basic and diluted, per share, compared to $12.2 million or $0.40, basic and diluted, per share in the third quarter of 2008. Revenues for the third quarter of 2009 totaled $5.4 million, compared to $17.5 million for the same period of 2008, reflecting a decrease in reimbursement revenue from Wyeth for RELISTOR(R) research and development under the recently terminated 2005 collaboration between Wyeth and Progenics. Operating loss was $13.2 million against $13.7 million a year ago. Net loss for the nine months ended September 30, 2009 was $30.0 million or $0.97, basic and diluted, per share, compared to a net loss of $30.1 million or $1.00, basic and diluted, per share for the first nine months of 2008. For the first nine months of 2009, the company reported revenues of $31.8 million compared to $60.8 million for the comparable period of 2008. Revenues for nine months also reflect a decrease in reimbursement and milestone revenue from Wyeth, offset by recognition in the first quarter of a $15.0 million upfront payment received in 2008 from Ono Pharmaceutical Co. Ltd. Operating loss was $31.7 million against $35.1 million a year ago.
Progenics Pharmaceuticals Inc. expected to Report Fiscal Year 2009 Results on March 8, 2010. This event was calculated by Capital IQ (Created on November 9, 2009).
11/9/2009
Progenics Pharmaceuticals Inc. expected to Report Fiscal Year 2009 Results on March 8, 2010. This event was calculated by Capital IQ (Created on November 9, 2009).
Progenics Pharmaceuticals Inc. - Special/M&A Call
10/14/2009
Progenics Pharmaceuticals Inc. - Special/M&A Calls
PGNX Competitors
| Company | Last | Change |
| Adolor Corporation | $1.51 USD | +0.01 |
| AVI BioPharma Inc | $1.46 USD | -0.09 |
| Cerus Corporation | $2.00 USD | -0.03 |
| Oncothyreon Inc | $4.70 USD | +0.04 |
| Trimeris Inc | $3.28 USD | +0.11 |
| Market data is delayed at least 20 minutes. | ||
Industry Analysis
| Valuation | PGNX | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | 3.2x |
|
| Price/Book | 1.2x |
|
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | 0.6x |
|
|
PGNX |
||
|
PGNX transactions
| Type Date |
Target | |
| No transactions in the last 6 months. | ||
More Recent News About Progenics Pharmaceuticals Inc.
More news for PGNX
Progenics regains rights to Relistor from Wyeth
Copyright © 2009 Yahoo! All rights reserved. Privacy Policy - Terms of Service - Copyright Policy - Report Problems Quotes and other information supplied by independent providers identified on the Yahoo! Finance partner page. Quotes are updated automatically, but will be turned off after 25 minutes of inactivity. Quote data delayed 15 minutes for Nasdaq, NYSE and Amex. Real-Time continuous streaming quotes are available through our premium service. You may turn streaming quotes on or off. All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Yahoo! is not an investment adviser and does not provide, endorse or review any information or data contained herein....Click here to read the whole Article (external link)
PROGENICS PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Show all filings for PROGENICS PHARMACEUTICALS INC | Request a Trial to NEW EDGAR Online Pro Form 8-K for PROGENICS PHARMACEUTICALS INC 14-Oct-2009Other Events, Financial Statements and Exhibits Copyright © 2009 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service - Copyright/IP Policy - Send Feedback SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is"...Click here to read the whole Article (external link)
Progenics Pharm downgraded by Needham
DateResearch FirmActionFromTo16-Mar-09OppenheimerDowngradeOutperformPerform16-Mar-09Brean MurrayDowngradeBuyHold12-Mar-09FTN Equity CapitalInitiatedNeutral2-Jul-08Friedman BillingsDowngradeMkt PerformUnderperform25-Apr-08CitigroupUpgradeSellHold12-Mar-08Lazard CapitalDowngradeBuyHold12-Mar-08Friedman BillingsDowngradeOutperformMkt Perform26-Sep-07Banc of America SecInitiatedBuy14-Feb-07Friedman BillingsInitiatedOutperform29-Jan-07RBC Capital MktsUpgradeSector PerformOutperform22-Dec-06First AlbanyInitiatedBuy6-Nov-06Am Tech/JSA ResearchInitiatedBuy14-Sep-06WR HambrechtInitiatedHold22-Aug-06Piper JaffrayInitiatedOutperform2-Aug-06Cowen & CoInitiatedOutperform27-Jul-06RBC Capital MktsInitiatedSector Perform1-Dec-05Stifel NicolausInitiatedOutperform/Buy1-Dec-05Banc of America SecInitiatedBuy7-Sep-05Needham & CoInitiatedBuy1-Sep-05Brean MurrayInitiatedStrong Buy30-Aug-05Morgan JosephInitiatedBuy15-Aug-05Adams HarknessDowngradeBuyMkt Perform14-Apr-05Adams HarknessInitiatedBuy2-Mar-05WachoviaInitiatedOutperform23-Feb-05CIBC Wrld MktsUpgradeSector PerformSector Outperform20-Jan-05Legg MasonUpgradeHoldBuy10-Aug-04Legg MasonDowngradeBuyHold23-Feb-04Fortis BankInitiatedStrong Buy7-Aug-01CE Unterberg TowbinDowngradeStrong BuyBuy25-Jul-01Ladenburg ThalmannInitiatedStrong Buy1-Mar-01Josephthal & CoInitiatedBuy25-Jan-01CIBC Wrld MktsUpgradeBuyStrong Buy25-Jul-00Ladenburg ThalmannInitiatedStrong Buy10-Jul-00CE Unterberg TowbinInitiatedStrong Buy26-May-00...Click here to read the whole Article (external link)
PROGENICS PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement
Item 1.01 Entry into a Material Definitive Agreement; Item 1.02 Termination of a Material Definitive Agreement. On October 9, 2009, Progenics Pharmaceuticals, Inc. and its subsidiaries, Progenics Pharmaceuticals Nevada, Inc. and Excelsior Life Sciences Ireland Limited (together, Progenics), entered into a Termination and Transition Agreement, effective as of October 1, 2009, with Wyeth Pharmaceuticals, a division of Wyeth, and its affiliates, Wyeth-Whitehall Pharmaceuticals, Inc., Wyeth-Ayerst Lederle, Inc., and AHP Manufacturing B.V. (together, Wyeth), providing for the termination of the December 23, 2005 License and Co-Development Agreement between them and the transition to Progenics of responsibility for the development and commercialization of RELISTOR® methylnaltrexone bromide for the treatment of opioid-induced side effects, including constipation and post-operative bowel dysfunction. Under the Termination Agreement, the 2005 Agreement and Wyeth's license of Progenics technology thereunder has terminated except as necessary for performance of Wyeth's obligations thereunder. Wyeth has granted to Progenics a fully-paid up, irrevocable, exclusive (except as to Wyeth and its affiliates) license to relevant technology generated by Wyeth alone or in conjunction with Progenics during the course of their 2005 Agreement collaboration and during Wyeth's performance of its Termination Agreement obligations, and agreed not to assert against Progenics or its affiliates, licensees or other third-party business partners any patent rights owned by Wyeth or its affiliates that would be infringed by unlicensed development or commercialization of RELISTOR. Progenics controls filing, prosecution, abandonment and enforcement against third party infringers of the patent rights related to its technology and those licensed to it by Wyeth. Wyeth has also assigned or agreed to assign to Progenics specified RELISTOR-related commercial intellectual property, including trademarks, Internet domain n...Click here to read the whole Article (external link)
Biotech Stock Mailbag: Oncothyreon
Stock quotes in this article: ONTY , HEB , PGNX , ...Click here to read the whole Article (external link)
CORRECTING and REPLACING Progenics Announces Third Quarter 2009 Financial Results
PROGENICS PHARMACEUTICALS, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited) (in thousands, except net loss per share) Â For the Three Months Ended September 30, Â For the Nine Months Ended September 30, 2009 Â 2008 2009 Â 2008 Revenues: Research and development $ 4,431 $ 16,015 $ 29,206 $ 54,896 Royalty income 509 44 ...Click here to read the whole Article (external link)
BioMed Realty Trust Extends Lease at Landmark With Progenics Pharmaceuticals
SAN DIEGO, Oct. 29 /PRNewswire-FirstCall/ -- BioMed Realty Trust, Inc. (NYSE: BMR - News) announced today that it has entered into a new ten-year lease with Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX - News) encompassing approximately 148,000 square feet at The Landmark at Eastview campus in Tarrytown, New York. This new lease replaces existing leases with Progenics which were set to expire from 2009 to 2012. (Logo: http://www.newscom.com/cgi-bin/prnh/20091005/BIOMEDLOGO)According to Alan D. Gold, BioMed's Chairman and Chief Executive Officer, "We are very pleased with our expanding relationship with Progenics, one of BioMed's premier large, publicly traded life science tenants. We look forward to further supporting their efforts to continue discovery for treatment of patients with debilitating conditions and life-threatening disease, with principle programs directed toward supportive care, virology and oncology."Paul J. Maddon, M.D., Ph.D., Progenics' Founder, Chief Ex...Click here to read the whole Article (external link)
PROGENICS PHARMACEUTICALS INC Financials
Copyright © 2009 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service - Copyright/IP Policy - Send Feedback Quotes delayed, except where indicated otherwise.Delay times are 15 mins for NASDAQ, 20 mins for NYSE and Amex. See also delay times for other exchanges.Fundamental company data provided by Capital IQ. Quotes and other information supplied by independent providers identified on the Yahoo! Finance partner page. Quotes are updated automatically, but will be turned off after 25 minutes of inactivity. Quotes are delayed at least 15 minutes. Real-...Click here to read the whole Article (external link)
PROGENICS PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition
Show all filings for PROGENICS PHARMACEUTICALS INC | Request a Trial to NEW EDGAR Online Pro Form 8-K for PROGENICS PHARMACEUTICALS INC 9-Nov-2009Results of Operations and Financial Condition Copyright © 2009 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service - Copyright/IP Policy - Send Feedback SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for in...Click here to read the whole Article (external link)
Would you like to leave a comment about Progenics Pharmaceuticals Inc. PGNX
Find out what social network information about Progenics Pharmaceuticals Inc. are available on RealpenniesWorst 5 - Click here to find out what stocks have been voted down by our visitors and users
Besides Progenics Pharmaceuticals Inc. there is more great information available at Realpennies.com